- Email: [email protected]
5196416 Transdermal flux-enhancing pharmaceutical compositions comprising azone, ethanol and water
New Patents
5196416 TRANSDERMAL FLUXENHANCING PHARMACEUTICAL COMPOSITIONS COMPRISING AZONE, ETHANOL AND WATER Kirti Valia assigned to Eli Lilly and Company Permeation enhancement compositions are disclosed. Said compositions include from 30 to 70 parts by weight ethanol, from 0.1 to 10 parts by weight azone, from 30 to 80 parts by weight water and optionally from 10 to 30 parts by weight propylene glycol, which compositions provide increased percutaneous absorption of a pharmacologically active agent disposed therewith.
5196417 PIROXICAM-CONTAINING PHARMACEUTICAL COMPOSITION FOR TOPICAL USE Reinhol Dolling, Uwe N Johann, Feldkirchen Westerham, Federal Republic Of Germany assigned to Sagitta Arzneimittel GmbH A pharmaceutical composition for topical application is described on the basis of a W/O emulsion, which contains piroxicam in the oil phase as an active ingredient. On account of its good compatibility to the skin and stability characteristics, the composition is very suitable for use as an antirheumatic, antiphlogistic and/or antiinflammatory pharmaceutical.
5196427 3-ARYL-4(3H) QUINAZOLINONE CCK ANTAGONISTS AND PHARMACEUTICAL FORMULATIONS THEREOF Melvin J Yu, Jefferson McCowan, K Jef Thrasher, ,mahretseW nehcrikdleF assigned to Eli Lilly and Company Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the
m
treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
5196444 I-(CYCLOHEXYLOXY CARBONYLOXY)ETHYL 2ETHOXY-I-((2' (1H-TETRAZOL-5 YL)BIPHENYL-4-YL) METHYL)BENZIMIDAZOLE 7-CAR BOXYLATE AND COMPOSITIONS AND METHODS OF PHARMACEUTICAL USE THEREOF Takehiko Naka, Kohei Nishikawa, Takeshi Kato, Feldkirchen Westerham, assigned to Takeda Chemical Industries Ltd 1-(Cyclohexyloxy carbonyloxy)ethyl 2-ethoxy1-((2'-(1H-tetrazol-5 yl)biphenyl-4-yl) methyl)benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
5196449 METHODS AND PHARMACEUTICAL C O M P O S I T I O N S FOR THE T R E A T M E N T OF O P H T H A L M I C DISEASES Maria J Magistretti, Marisa Conti, Giorgio Pifferi, ,mahretseW nehcrikdleF assigned to IdB Holding SpA The anthocyanidins pelargonidin and delphidin, have been found to possess novel and unexpected activity in the ophthalmic field, specifically that they are active in reducing the permeability of ciliary body vessels. According to one aspect of the present invention there is provided a method of reducing the hyperpermeability of the ciliary body ocular vessels in a subject which comprises administering to the subject an effective dose of pelargonidin or delphidin. The invention further provides the use of pelargonidin or delphidin in the manufacture of pharma-
5196416 TRANSDERMAL FLUXENHANCING PHARMACEUTICAL COMPOSITIONS COMPRISING AZONE, ETHANOL AND WATER Kirti Valia assigned to Eli Lilly and Company Permeation enhancement compositions are disclosed. Said compositions include from 30 to 70 parts by weight ethanol, from 0.1 to 10 parts by weight azone, from 30 to 80 parts by weight water and optionally from 10 to 30 parts by weight propylene glycol, which compositions provide increased percutaneous absorption of a pharmacologically active agent disposed therewith.
5196417 PIROXICAM-CONTAINING PHARMACEUTICAL COMPOSITION FOR TOPICAL USE Reinhol Dolling, Uwe N Johann, Feldkirchen Westerham, Federal Republic Of Germany assigned to Sagitta Arzneimittel GmbH A pharmaceutical composition for topical application is described on the basis of a W/O emulsion, which contains piroxicam in the oil phase as an active ingredient. On account of its good compatibility to the skin and stability characteristics, the composition is very suitable for use as an antirheumatic, antiphlogistic and/or antiinflammatory pharmaceutical.
5196427 3-ARYL-4(3H) QUINAZOLINONE CCK ANTAGONISTS AND PHARMACEUTICAL FORMULATIONS THEREOF Melvin J Yu, Jefferson McCowan, K Jef Thrasher, ,mahretseW nehcrikdleF assigned to Eli Lilly and Company Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the
m
treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.
5196444 I-(CYCLOHEXYLOXY CARBONYLOXY)ETHYL 2ETHOXY-I-((2' (1H-TETRAZOL-5 YL)BIPHENYL-4-YL) METHYL)BENZIMIDAZOLE 7-CAR BOXYLATE AND COMPOSITIONS AND METHODS OF PHARMACEUTICAL USE THEREOF Takehiko Naka, Kohei Nishikawa, Takeshi Kato, Feldkirchen Westerham, assigned to Takeda Chemical Industries Ltd 1-(Cyclohexyloxy carbonyloxy)ethyl 2-ethoxy1-((2'-(1H-tetrazol-5 yl)biphenyl-4-yl) methyl)benzimidazole-7-car boxylate or a pharmaceutically acceptable salt thereof has potent angiotensin II antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
5196449 METHODS AND PHARMACEUTICAL C O M P O S I T I O N S FOR THE T R E A T M E N T OF O P H T H A L M I C DISEASES Maria J Magistretti, Marisa Conti, Giorgio Pifferi, ,mahretseW nehcrikdleF assigned to IdB Holding SpA The anthocyanidins pelargonidin and delphidin, have been found to possess novel and unexpected activity in the ophthalmic field, specifically that they are active in reducing the permeability of ciliary body vessels. According to one aspect of the present invention there is provided a method of reducing the hyperpermeability of the ciliary body ocular vessels in a subject which comprises administering to the subject an effective dose of pelargonidin or delphidin. The invention further provides the use of pelargonidin or delphidin in the manufacture of pharma-